Free Trial
NYSE:DNA

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

Ginkgo Bioworks logo
$7.44 +0.65 (+9.57%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$7.58 +0.14 (+1.81%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ginkgo Bioworks Stock (NYSE:DNA)

Key Stats

Today's Range
$6.89
$7.59
50-Day Range
$5.54
$8.37
52-Week Range
$5.00
$24.85
Volume
1.27 million shs
Average Volume
1.45 million shs
Market Capitalization
$435.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.77
Consensus Rating
Reduce

Company Overview

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

Ginkgo Bioworks Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

DNA MarketRank™: 

Ginkgo Bioworks scored higher than 18% of companies evaluated by MarketBeat, and ranked 844th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ginkgo Bioworks has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, no hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Ginkgo Bioworks has received no research coverage in the past 90 days.

  • Read more about Ginkgo Bioworks' stock forecast and price target.
  • Earnings Growth

    Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($10.02) to ($5.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ginkgo Bioworks is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ginkgo Bioworks is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ginkgo Bioworks has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ginkgo Bioworks' valuation and earnings.
  • Percentage of Shares Shorted

    30.71% of the float of Ginkgo Bioworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Ginkgo Bioworks has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Ginkgo Bioworks has recently decreased by 1.20%, indicating that investor sentiment is improving.
  • Dividend Yield

    Ginkgo Bioworks does not currently pay a dividend.

  • Dividend Growth

    Ginkgo Bioworks does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    30.71% of the float of Ginkgo Bioworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Ginkgo Bioworks has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Ginkgo Bioworks has recently decreased by 1.20%, indicating that investor sentiment is improving.
  • News Sentiment

    Ginkgo Bioworks has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Ginkgo Bioworks this week, compared to 6 articles on an average week.
  • Search Interest

    8 people have searched for DNA on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,308.00 in company stock.

  • Percentage Held by Insiders

    Only 9.72% of the stock of Ginkgo Bioworks is held by insiders.

  • Percentage Held by Institutions

    78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ginkgo Bioworks' insider trading history.
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

DNA Stock News Headlines

Ginkgo Bioworks appoints Steven Coen as new CFO
Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
See More Headlines

DNA Stock Analysis - Frequently Asked Questions

Ginkgo Bioworks' stock was trading at $9.82 at the start of the year. Since then, DNA stock has decreased by 24.2% and is now trading at $7.44.
View the best growth stocks for 2025 here
.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its earnings results on Tuesday, May, 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by $0.35. The firm had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. Ginkgo Bioworks had a negative trailing twelve-month return on equity of 58.54% and a negative net margin of 298.78%.
Read the conference call transcript
.

Top institutional investors of Ginkgo Bioworks include Baillie Gifford & Co. (5.77%), Erste Asset Management GmbH (2.84%), EcoR1 Capital LLC (2.52%) and Millennium Management LLC (2.46%). Insiders that own company stock include Reshma P Shetty, Barry Canton, Marijn E Dekkers, Jason R Kelly, Christian O Henry, Mark E Dmytruk, Harry Sloan, Marie E Fallon and Steven P Coen.
View institutional ownership trends
.

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Enovix (ENVX), Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST) and Globant (GLOB).

Company Calendar

Last Earnings
5/06/2025
Today
5/28/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:DNA
Fax
N/A
Employees
640
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.77
High Stock Price Target
$10.00
Low Stock Price Target
$0.30
Potential Upside/Downside
-22.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$892.87 million
Net Margins
-298.78%
Pretax Margin
-298.94%

Debt

Sales & Book Value

Annual Sales
$237.42 million
Price / Cash Flow
N/A
Book Value
$21.93 per share
Price / Book
0.34

Miscellaneous

Free Float
51,892,000
Market Cap
$435.48 million
Optionable
Optionable
Beta
1.29
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NYSE:DNA) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners